Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Dilley, SE, Havrilesky, LJ, Bakkum-Gamez, J, Cohn, DE, Michael Straughn, J, Caughey, AB, and Rodriguez, MI. "Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention." Gynecologic oncology 146, no. 2 (August 2017): 373-379.

Full Text

Davidson, BA, Ehrisman, J, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Li, X, Havrilesky, LJ, and Hall, AHS. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer." International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists (July 11, 2017).

Full Text

Havrilesky, LJ, Moss, HA, Chino, J, Myers, ER, and Kauff, ND. "Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers." Gynecologic oncology 145, no. 3 (June 2017): 549-554.

Full Text

Wenzel, L, Mukamel, D, Osann, K, Havrilesky, L, Sparks, L, Lipscomb, J, Wright, AA, Walker, J, Alvarez, R, Van Le, L, Robison, K, Bristow, R, Morgan, R, Rimel, BJ, Ladd, H, Hsieh, S, Wahi, A, and Cohn, D. "Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients." Contemporary clinical trials 57 (June 2017): 29-36.

Full Text

Hong, JC, Foote, J, Broadwater, G, Gaillard, S, Havrilesky, LJ, and Chino, JP. "Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 27, no. 4 (May 2017): 720-729.

Full Text

Berchuck, A, Havrilesky, LJ, and Kauff, ND. "Is There a Role for Ovarian Cancer Screening in High-Risk Women?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 13 (May 2017): 1384-1386.

Full Text

Natesan, D, Hong, JC, Foote, J, Sosa, JA, Havrilesky, L, and Chino, J. "Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 27, no. 4 (May 2017): 794-804.

Full Text

Cohn, DE, Ko, E, Meyer, LA, Wright, JD, Temkin, SM, Foote, J, Jones, NL, and Havrilesky, LJ. "The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations." Gynecologic oncology 145, no. 1 (April 2017): 185-191. (Review)

Full Text

Pierce, SR, Stine, JE, Gehrig, PA, Havrilesky, LJ, Secord, AA, Nakayama, J, Snavely, AC, Moore, DT, and Kim, KH. "Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma." Gynecologic oncology 144, no. 3 (March 2017): 531-535.

Full Text

Foote, JR, Lopez-Acevedo, M, Buchanan, AH, Secord, AA, Lee, PS, Fountain, C, Myers, ER, Cohn, DE, Reed, SD, and Havrilesky, LJ. "Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer." Journal of Oncology Practice 13, no. 2 (February 2017): e120-e129.

Full Text

Pages